Thiazolidinedione, a drug for treating type II diabetes, has been proven to KLF11 expression, which may be applied in the treatment of KLF11 silencing‐mediated formation of OS CSCs.203, 265. The gene discussed is KLF11; the disease is type 2 diabetes mellitus.